Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera in Unlicensed NET Indications
NCT06121271Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), Paraganglioma (PGL), pheochromocytoma, medullary thyroid carcinoma (MTC), sponsored by University College London. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)Paraganglioma (PGL)pheochromocytomamedullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT06121271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121271.